Home / Stocks / ZTS

Zoetis (ZTS, Pharmaceuticals) Stock Valuation & Fair Value Quality business with a solid forward outlook

Zoetis (ZTS, Pharmaceuticals) trades at a blended P/E of 12.0, about 61% below its historical normal valuation, with a forward growth estimate of 3.8% and a PEG of 3.14. Analysts' one-year estimates have been hit 82% of the time.

DATA AS OF 2026-08-21
Blended P/E
12.0
Normal P/E
30.6
PEG
3.14
Fwd growth
3.8%
Div yield
2.8%
RSI (14)
46.7
Neutral

The Street vs SeerForecast

Wall Street's mean price target for ZTS is $100.94 across 16 analysts, 29.9% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: quality business with a solid forward outlook. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been quality business with a solid forward outlook since 2026-06-03.

Price and rating by weekClose moved -4.2 percent from 2026-06-03 to 2026-08-17, with 0 rating changes over 21 recorded weeks.2026-06-03: Quality business with a solid forward outlook, close 77.05 (recalculated)2026-06-10: Quality business with a solid forward outlook, close 80.73 (recalculated)2026-06-14: Quality business with a solid forward outlook, close 79.02 (recalculated)2026-06-16: Quality business with a solid forward outlook, close 78.78 (recalculated)2026-06-21: Quality business with a solid forward outlook, close 78.17 (recalculated)2026-07-02: Quality business with a solid forward outlook, close 74.28 (recalculated)2026-07-06: Quality business with a solid forward outlook, close 74.90 (recalculated)2026-07-09: Quality business with a solid forward outlook, close 74.56 (recalculated)2026-07-12: Quality business with a solid forward outlook, close 75.04 (recalculated)2026-07-13: Quality business with a solid forward outlook, close 74.87 (recalculated)2026-07-14: Quality business with a solid forward outlook, close 73.56 (recalculated)2026-07-20: Quality business with a solid forward outlook, close 76.20 (recalculated)2026-07-22: Quality business with a solid forward outlook, close 74.19 (recalculated)2026-07-25: Quality business with a solid forward outlook, close 75.35 (recalculated)2026-07-27: Quality business with a solid forward outlook, close 76.92 (recalculated)2026-07-31: Quality business with a solid forward outlook, close 77.29 (recalculated)2026-08-03: Quality business with a solid forward outlook, close 77.292026-08-07: Quality business with a solid forward outlook, close 72.66 (recalculated)2026-08-10: Quality business with a solid forward outlook, close 72.662026-08-14: Quality business with a solid forward outlook, close 73.79 (recalculated)2026-08-17: Quality business with a solid forward outlook, close 73.7977742026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 11.8-61%Quality business with a solid forward outlook
2026-06-10P/E 12.0-61%Quality business with a solid forward outlook
2026-06-14P/E 12.0-61%Quality business with a solid forward outlook
2026-06-16P/E 12.0-61%Quality business with a solid forward outlook
2026-06-21P/E 12.0-61%Quality business with a solid forward outlook
2026-07-02P/E 10.9-64%Quality business with a solid forward outlook
2026-07-06P/E 11.3-63%Quality business with a solid forward outlook
2026-07-09P/E 11.3-63%Quality business with a solid forward outlook
2026-07-12P/E 11.3-63%Quality business with a solid forward outlook
2026-07-13P/E 11.3-63%Quality business with a solid forward outlook
2026-07-14P/E 11.3-63%Quality business with a solid forward outlook
2026-07-20P/E 11.5-62%Quality business with a solid forward outlook
2026-07-22P/E 11.5-62%Quality business with a solid forward outlook
2026-07-25P/E 11.3-63%Quality business with a solid forward outlook
2026-07-27P/E 11.3-63%Quality business with a solid forward outlook
2026-07-31P/E 11.4-63%Quality business with a solid forward outlook
2026-08-03P/E 11.6-62%Quality business with a solid forward outlook
2026-08-07P/E 11.6-62%Quality business with a solid forward outlook
2026-08-10P/E 11.5-62%Quality business with a solid forward outlook
2026-08-14P/E 12.1-61%Quality business with a solid forward outlook
2026-08-17P/E 11.7-62%Quality business with a solid forward outlook
2026-08-21P/E 12.0-61%Quality business with a solid forward outlook ← now

Frequently asked questions

Is Zoetis stock overvalued?

At a blended P/E of 12.0 versus its historical normal P/E of 30.6, Zoetis trades about 61% below its typical valuation, with a PEG of 3.14 on 3.8% forward growth. tickerseer currently rates it quality business with a solid forward outlook.

What is Zoetis's fair value and PEG?

Zoetis trades at a blended P/E of 12.0 against a historical normal P/E of 30.6, a PEG of 3.14, and a forward growth estimate of 3.8%.

Has tickerseer's rating of Zoetis changed?

tickerseer's rating has been quality business with a solid forward outlook since 2026-06-03.

What is the analyst price target for Zoetis?

The mean Wall Street price target for Zoetis is $100.94 across 16 analysts, 29.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ZTS free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.